BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36824011)

  • 1. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
    He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
    J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
    Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
    Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
    Niu L; Wu Z
    Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
    Ouyang D; Li R; Li Y; Zhu X
    J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human
    Rathbun LA; Magliocco AM; Bamezai AK
    Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
    Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
    Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
    Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
    Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a 4-miRNA prognostic signature for endometrial cancer.
    Huang J; Du F; Wang N
    Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
    Tian Y; Wen F; Wang S; Lv N
    Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
    Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
    Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel key genes associated with uterine corpus endometrial carcinoma progression and prognosis.
    Li H; Zhou Q; Wu Z; Lu X
    Ann Transl Med; 2023 Jan; 11(2):100. PubMed ID: 36819577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
    Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
    Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m
    Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
    BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.